Since these clinical trials were not designed solely to investigate the role of PD-1/PD-L1 blockade immunotherapy in EGFR mutant NSCLC patients, the efficacy in EGFR mutant patients was revealed by patient subgroup analysis. Here, CD274 is linked to non-small cell lung carcinoma.